Second-line therapy in gemcitabine-pretreated patients with advanced pancreatic cancer

Journal of Clinical Oncology

Volumn 26, Issue 7, 2008, Pages 1178-1179

  Boeck, Stefan ^a   Heinemann, Volker ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; ERLOTINIB; EXATECAN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; MARIMASTAT; OXALIPLATIN; PEMETREXED; TIPIFARNIB; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADVANCED CANCER; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; DETERIORATION; HUMAN; LETTER; PANCREAS CANCER; PRIORITY JOURNAL; SALVAGE THERAPY; TREATMENT RESPONSE; ADENOCARCINOMA; NOTE; PANCREAS TUMOR; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ADENOCARCINOMA; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DEOXYCYTIDINE; HUMANS; PANCREATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SALVAGE THERAPY;

EID: 41949106225     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.15.3304     Document Type: Letter

References (7)

1. Kulke MH, Blaszkowsky LS, Ryan DR, et al: Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol 25:4787-4792, 2007
2. Oettle H, Pelzer U, Stieler J, et al: Oxaliplatin/folinic acid/5-fluorouracil [24h] (OFF) plus best supportive care versus best supportive care alone (BSC) in second-line therapy of gemcitabine-refractory advanced pancreatic cancer (CONKO 003). J Clin Oncol 23:315s, 2005 (suppl; abstr 4031)
3. Boeck S, Weigang-Köhler K, Fuchs M, et al: Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: A multicenter phase II trial. Ann Oncol 18:745-751, 2007
4. Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical trials group. J Clin Oncol 25:1960-1966, 2007
5. Heinemann V, Quietzsch D, Gieseler F, et al: Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 24:3946-3952, 2006
6. Herrmann R, Bodoky G, Ruhstaller T, et al: Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: A randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Res and the Central European Cooperative Oncology Group. J Clin Oncol 25:2212-2217, 2007
7. Riess H, Pelzer U, Stieler J, et al: A randomized second line trial in patients with gemcitabine refractory advanced pancreatic cancer: CONKO 003. J Clin Oncol 25:201s, 2007 (suppl; abstr 4517)